Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree...trailing stops are much better than a stop loss.
That's a million dollar question. Lol We fell below the 50-day MA today. Unless we get any news it "could" touch the 200 day MA($.39-40) which would be a nice place to add. If we get news then obviously that's not gonna happen.
Also depends on buying/selling. Would be nice to see some consolidation which would make me feel good about a buy here at this level. Still too much volatility. There was significant selling today while the past few days have been absent of the kind of total volume we saw today.
At any rate we will climb up soon enough.
GL to ya!
I have this on close watch to add to my position depending on action ;)
Ihub is showing it as a sell. Is that what your seeing?
Nicely put....
SYN...daily chart looks much like it did during sessions prior to the offering IMO. I'm with Bob it wants to get back to $4...
GLE
You taking about GG? ;)
WolfWayne...you can follow it here if you'd like...http://www.otcmarkets.com/stock/AVXL/quote
Agreed and was actually thinking those exact thoughts just moments ago. I feel like we should see nice movement this week and moving forward with the catalyst in the very near future.
GLE
SYN...it is closed.
http://www.syntheticbiologics.com/index.php?s=43&item=240
He had several entry and exits but upon selling 3 times he had gains of 150%, 200% and 400%. He entered some at .33 and .42.
Risky chick...The list was for Buyout Targets not current positions...
SYN... Data out soon on SYN 004. Primary completion this month.
http://www.syntheticbiologics.com/2015-03-30-Synthetic-Biologics-Initiates-Phase-2a-Clinical-Trial-of-SYN-004-to-Protect-the-Microbiome-and-Prevent-C-difficile
https://clinicaltrials.gov/ct2/show/NCT02473640?term=SYN+004&rank=2
Additionally, MRI results are out on Trimesta. Expecting partnership soon as well. The deadline to have all data from the MRI analysis is due by August 1st. I expect full data will be needed to negotiate full partnership for Trimesta. Additionally the capital raise just completed is surely not enough funds to have the various clinical trials pushed through. Partnership must be in the works. AIMO
8k regarding Trimesta details...
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=10374925&type=HTML&symbol=SYN&companyName=Synthetic+Biologics+Inc.&formType=8-K&dateFiled=2015-07-09
Thanks for pulling that info out of the 8k for everyone to see...I think the sheer volume today speaks volume of the amount of interest and anticipation of things to come. I want to add more but have funds tied up for a bit in another position. If it looks like we are gonna start the run again I will add to my position.
I always appreciate the board regulars posting their points of view as I like hearing various perspectives. Which is why I think this is a great board and am certainly glad to be here!
I'm in thru data as well...
It's a long answer but basically allows for exclusivity, incentives and easier to get approved. The drug must be treating a disease state with fewer than 200k ppl in the U.S.
Read the following 2 links for specifics.
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm
https://en.m.wikipedia.org/wiki/Orphan_drug
Nice call Binks!
Phase 2b will have to be completed in this case. Disease state and how aggressive or deadly it is are usually the only possibility for skipping through a trial. Not to say this disease state isn't that but the disease progression is over a longer period of time then say aggressive type cancers for example.
Phase IIb in this particular trial is the portion that is the collection of various data points and many of which will be used to design the best trial for a phase III by giving the correct dosage for optimal response aka efficacy. They will have to have this information for not only the FDA but for making sure they have the best chance to move into phase III and increase their likelihood achieve success.
AIMO
Everybody has their own rules. Gotta stick to your plan. Good move!
I'll be holding myself. I may add to my trading position once I see the offering price and action. News is imminent and the remainder of the year has too many catalyst.
Best of luck to ya!
That just took out a lot of ppls stops. That felt orchestrated...
It's a suicide mission if they are but I believe that's what's happening. I think they will cover soon enough. SYN
SYN...I think volume will be higher than yesterday's. I believe this move started because of the high short interest at the end of June. When the 8k came out last week they started covering and the ones on the sidelines started hopping in because the price action started to move up. Good things still to come in the form of news in my opinion. I feel $6+ over the next 30 days...AIMO of course!
These next 6 months are gonna be action packed!!...and your right we knew it was coming. Patience pays$$$$$$
RCPT...Celgene to buy Receptos for $7.2 billion; gains promising drug...
http://mobile.reuters.com/article/idUSKCN0PO2OB20150714?irpc=932
RCPT...Celgene to buy Receptos for $7.2 billion; Gains promising Drug...
http://mobile.reuters.com/article/idUSKCN0PO2OB20150714?irpc=932
Thanks Bob! Did you ever get in or are you waiting until after MRI results are released?
SYN wall got taken out...she's gtg now
Great advice!!!!
Close above the old 52 week high! Nice!
Quite the wall at $3.50....269k on the ask
Your posts give me a good chuckle....lol
80% of my SYN is long term. 20% for trading. Still holding my trading shares until after partnership announcement. If there's a good cash infusion from partnership it would push the possibility of a raise out into the future. It will also add more value. Gonna stick it out.
Good luck on SNGX. I think it holds a lot of promise. I will be watching it for now. Can't be in all the movers ;)
SYN moving nicely and showing strength. 2 days of a nice uptick in volume....
GLE
It certainly has the appearances that something. Has leaked...I'll be watching after the close for a PR.
Of course this is speculation but I'm here for the long term anyway.
Good times ahead!!!
I've heard 80% of statistics are made up anyway... ;)
I like basing my investments in facts not speculation and agree that keeping everything as grounded as possible based on substance provides greater benefit to those assessing the company.
Ziggy...the odds of the trial advancing to PIII before PIIb is completed is very slim in my opinion. PIIb is the portion of the trial looks at dose response and importantly efficacy. I know that since it's an open label study they can see data as the trial progresses. However, the FDA in my opinion is gonna want all the facts before PIII. Anything is possible I guess but that is speculation and I try not to speculate on timelines as they lead to emotional responses and cloud judgement.
I do think we may get some implications to the ongoing trial in regards to early signs of efficacy from the presentation this month. How much info in this regard is still to be determined.
This info was pulled directly from the company's website....
The multicenter Phase 2a clinical trial of ANAVEX 2-73 consists of two parts, in which at least 32 mild to moderate Alzheimer’s patients will be enrolled. The first part (PART A) is a simple randomized, open-label, two-period, cross-over, adaptive trial lasting up to 36 days for each patient. The second part (PART B) is an open-label extension for an additional 26 weeks, so as to establish a longer drug effect for the patients who wish to continue on an oral daily dose.
The primary objective of the trial is to evaluate the maximum tolerated dose of ANAVEX 2-73 in these patients. Secondary trial objectives include dose response, bioavailability, exploratory cognitive efficacy using mini-mental state examination score (MMSE) and electroencephalographic (EEG) activity, including event-related potentials (EEG/ERP), as well as the relationship of ANAVEX 2-73 as an add-on therapy to donepezil, the current standard of care.
Good luck! Long AVXL!
Edit..26 "week" open label extension...
They will not be in PIII u til next year. Phase IIb is a 26 open label extension study. At earliest Q1-Q2 of 2016. IMO
Checking them out now Ron...
At a quick glance I had a couple questions...
do you know how there revenue model is setup in the developments try have ongoing with these partners? Is it royalty based and the cost are covered by the collaborator such as Abbvie?
I agree it would have huge implications across many disease states and I'm just trying to gather how that translates into assessing the company's potential value.
35% insider ownership bodes well IMO...